Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

September 2011 - FRMC

09/19/2011

Christin Melton

Christin Melton
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking...
09/19/2011
First Report Managed Care
09/19/2011

Christin Melton

Christin Melton
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used...
09/19/2011
First Report Managed Care
09/19/2011

Christin Melton

Christin Melton
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized,...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of...
09/19/2011
First Report Managed Care
09/19/2011

Tim Casey

Tim Casey
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year...
09/19/2011
First Report Managed Care

Advertisement

Advertisement

Advertisement